We are analyzing https://link.springer.com/article/10.1007/s11864-017-0458-0.

Title:
Checkpoint Inhibitors for the Treatment of Renal Cell Carcinoma | Current Treatment Options in Oncology
Description:
The advent of checkpoint inhibitors has revolutionized systemic therapy for many malignancies, including renal cell carcinoma (RCC) where multiple PD-1, PD-L1, and CTLA-4 inhibitors have demonstrated responses and improved survival for patients in clinical trials. Durable benefit with manageable toxicity can be achieved with these agents—but unfortunately for only a minority of individuals. Efforts are ongoing to understand mechanisms driving the response and resistance to checkpoint inhibitors in order to personalize therapy and extend benefit to more patients. In particular, combination immunotherapy is an area of active study with multiple ongoing trials in RCC. Novel immunotherapeutic agents are being explored as well. Clinically, there are nuances related to the use of immunotherapy that are important to understand in order to provide optimal care to patients. Potential autoimmune toxicities are important to identify early so they can be best mitigated with immunosuppression, and careful review of imaging with clinical correlation is important to ensure responding patients are not taken off treatment prematurely due to “pseudo-progression.” Lastly, although immunotherapy is an important new tool, it exists among other active agents in the treatment of RCC, and further study is needed to understand where it best fits in the treatment paradigm. In this article, we review the most recent data for immune checkpoint inhibitors in metastatic renal cell carcinoma and more broadly discuss the rapidly evolving landscape of immunotherapy in RCC, including combination immunotherapies.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Education
Health & Fitness
Science

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 7,626,182 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We find it hard to spot revenue streams.

Many websites are intended to earn money, but some serve to share ideas or build connections. Websites exist for all kinds of purposes. This might be one of them. Link.springer.com might be plotting its profit, but the way they're doing it isn't detectable yet.

Keywords {🔍}

article, pubmed, google, scholar, cell, carcinoma, renal, cas, cancer, metastatic, patients, clin, phase, oncol, immunotherapy, study, advanced, treatment, nivolumab, combination, central, trial, immune, results, med, suppl, received, interferon, tumors, content, checkpoint, inhibitors, therapy, rcc, engl, pembrolizumab, res, immunol, solid, privacy, cookies, data, pdl, ctla, clinical, versus, sunitinib, renalcell, meeting, pfizer,

Topics {✒️}

high-dose recombinant interleukin-2 month download article/chapter metastatic renal-cell carcinoma interferon-alfa-based immunotherapy compared metastatic renal-cell cancer advanced renal-cell carcinoma ifn gamma-stimulated genes tcr-induced stop signal reverse stop-signal model anti-pd-1 monoclonal antibody gov/statfacts/html/kidrp renal cell carcinoma immune-related response criteria interferon alfa-2b compared pd-l1 promote tolerance higher pd-l1 expression long-term survival update received institution-directed funds activate anti-tumor immunity full article pdf pd-l1 inhibitor atezolizumab renal pelvis cancer privacy choices/manage cookies revolutionized systemic therapy motzer rj wolchok jd immune therapy activity pd-1/b7-h1 anti-ctla4 antibody phase ii trial metastatic ccrcc lesions interferon alfa compared interferon alfa-2b immune checkpoint inhibitors tumor b7-h1 animal subjects performed immune-related response genitourinary cancers access long-term follow interferon alfa-2a article ghatalia mol cancer ther lag-3 regulates cd8+ anti-pd1 antibodies pd-l1 expression received financial support provide optimal care rapidly evolving landscape recommended reading papers samples revealed evidence

Questions {❓}

What happens when we stop?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Checkpoint Inhibitors for the Treatment of Renal Cell Carcinoma
         description:The advent of checkpoint inhibitors has revolutionized systemic therapy for many malignancies, including renal cell carcinoma (RCC) where multiple PD-1, PD-L1, and CTLA-4 inhibitors have demonstrated responses and improved survival for patients in clinical trials. Durable benefit with manageable toxicity can be achieved with these agents—but unfortunately for only a minority of individuals. Efforts are ongoing to understand mechanisms driving the response and resistance to checkpoint inhibitors in order to personalize therapy and extend benefit to more patients. In particular, combination immunotherapy is an area of active study with multiple ongoing trials in RCC. Novel immunotherapeutic agents are being explored as well. Clinically, there are nuances related to the use of immunotherapy that are important to understand in order to provide optimal care to patients. Potential autoimmune toxicities are important to identify early so they can be best mitigated with immunosuppression, and careful review of imaging with clinical correlation is important to ensure responding patients are not taken off treatment prematurely due to “pseudo-progression.” Lastly, although immunotherapy is an important new tool, it exists among other active agents in the treatment of RCC, and further study is needed to understand where it best fits in the treatment paradigm. In this article, we review the most recent data for immune checkpoint inhibitors in metastatic renal cell carcinoma and more broadly discuss the rapidly evolving landscape of immunotherapy in RCC, including combination immunotherapies.
         datePublished:2017-02-16T00:00:00Z
         dateModified:2017-02-16T00:00:00Z
         pageStart:1
         pageEnd:14
         sameAs:https://doi.org/10.1007/s11864-017-0458-0
         keywords:
            VEGF
            Cytotoxic T-lymphocyte associated protein 4
            Immune checkpoint blockade
            Immunotherapy
            Programmed death 1
            Renal cell carcinoma
            Oncology
         image:
         isPartOf:
            name:Current Treatment Options in Oncology
            issn:
               1534-6277
               1527-2729
            volumeNumber:18
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer US
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Pooja Ghatalia
               affiliation:
                     name:Fox Chase Cancer Center, Temple Health
                     address:
                        name:Department of Hematology/Oncology, Fox Chase Cancer Center, Temple Health, Philadelphia, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Matthew Zibelman
               affiliation:
                     name:Fox Chase Cancer Center, Temple Health
                     address:
                        name:Department of Hematology/Oncology, Fox Chase Cancer Center, Temple Health, Philadelphia, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Daniel M. Geynisman
               affiliation:
                     name:Fox Chase Cancer Center, Temple Health
                     address:
                        name:Department of Hematology/Oncology, Fox Chase Cancer Center, Temple Health, Philadelphia, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Elizabeth R. Plimack
               affiliation:
                     name:Fox Chase Cancer Center, Temple Health
                     address:
                        name:Department of Hematology/Oncology, Fox Chase Cancer Center, Temple Health, Philadelphia, USA
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Checkpoint Inhibitors for the Treatment of Renal Cell Carcinoma
      description:The advent of checkpoint inhibitors has revolutionized systemic therapy for many malignancies, including renal cell carcinoma (RCC) where multiple PD-1, PD-L1, and CTLA-4 inhibitors have demonstrated responses and improved survival for patients in clinical trials. Durable benefit with manageable toxicity can be achieved with these agents—but unfortunately for only a minority of individuals. Efforts are ongoing to understand mechanisms driving the response and resistance to checkpoint inhibitors in order to personalize therapy and extend benefit to more patients. In particular, combination immunotherapy is an area of active study with multiple ongoing trials in RCC. Novel immunotherapeutic agents are being explored as well. Clinically, there are nuances related to the use of immunotherapy that are important to understand in order to provide optimal care to patients. Potential autoimmune toxicities are important to identify early so they can be best mitigated with immunosuppression, and careful review of imaging with clinical correlation is important to ensure responding patients are not taken off treatment prematurely due to “pseudo-progression.” Lastly, although immunotherapy is an important new tool, it exists among other active agents in the treatment of RCC, and further study is needed to understand where it best fits in the treatment paradigm. In this article, we review the most recent data for immune checkpoint inhibitors in metastatic renal cell carcinoma and more broadly discuss the rapidly evolving landscape of immunotherapy in RCC, including combination immunotherapies.
      datePublished:2017-02-16T00:00:00Z
      dateModified:2017-02-16T00:00:00Z
      pageStart:1
      pageEnd:14
      sameAs:https://doi.org/10.1007/s11864-017-0458-0
      keywords:
         VEGF
         Cytotoxic T-lymphocyte associated protein 4
         Immune checkpoint blockade
         Immunotherapy
         Programmed death 1
         Renal cell carcinoma
         Oncology
      image:
      isPartOf:
         name:Current Treatment Options in Oncology
         issn:
            1534-6277
            1527-2729
         volumeNumber:18
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer US
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Pooja Ghatalia
            affiliation:
                  name:Fox Chase Cancer Center, Temple Health
                  address:
                     name:Department of Hematology/Oncology, Fox Chase Cancer Center, Temple Health, Philadelphia, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Matthew Zibelman
            affiliation:
                  name:Fox Chase Cancer Center, Temple Health
                  address:
                     name:Department of Hematology/Oncology, Fox Chase Cancer Center, Temple Health, Philadelphia, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Daniel M. Geynisman
            affiliation:
                  name:Fox Chase Cancer Center, Temple Health
                  address:
                     name:Department of Hematology/Oncology, Fox Chase Cancer Center, Temple Health, Philadelphia, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Elizabeth R. Plimack
            affiliation:
                  name:Fox Chase Cancer Center, Temple Health
                  address:
                     name:Department of Hematology/Oncology, Fox Chase Cancer Center, Temple Health, Philadelphia, USA
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Current Treatment Options in Oncology
      issn:
         1534-6277
         1527-2729
      volumeNumber:18
Organization:
      name:Springer US
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Fox Chase Cancer Center, Temple Health
      address:
         name:Department of Hematology/Oncology, Fox Chase Cancer Center, Temple Health, Philadelphia, USA
         type:PostalAddress
      name:Fox Chase Cancer Center, Temple Health
      address:
         name:Department of Hematology/Oncology, Fox Chase Cancer Center, Temple Health, Philadelphia, USA
         type:PostalAddress
      name:Fox Chase Cancer Center, Temple Health
      address:
         name:Department of Hematology/Oncology, Fox Chase Cancer Center, Temple Health, Philadelphia, USA
         type:PostalAddress
      name:Fox Chase Cancer Center, Temple Health
      address:
         name:Department of Hematology/Oncology, Fox Chase Cancer Center, Temple Health, Philadelphia, USA
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Pooja Ghatalia
      affiliation:
            name:Fox Chase Cancer Center, Temple Health
            address:
               name:Department of Hematology/Oncology, Fox Chase Cancer Center, Temple Health, Philadelphia, USA
               type:PostalAddress
            type:Organization
      name:Matthew Zibelman
      affiliation:
            name:Fox Chase Cancer Center, Temple Health
            address:
               name:Department of Hematology/Oncology, Fox Chase Cancer Center, Temple Health, Philadelphia, USA
               type:PostalAddress
            type:Organization
      name:Daniel M. Geynisman
      affiliation:
            name:Fox Chase Cancer Center, Temple Health
            address:
               name:Department of Hematology/Oncology, Fox Chase Cancer Center, Temple Health, Philadelphia, USA
               type:PostalAddress
            type:Organization
      name:Elizabeth R. Plimack
      affiliation:
            name:Fox Chase Cancer Center, Temple Health
            address:
               name:Department of Hematology/Oncology, Fox Chase Cancer Center, Temple Health, Philadelphia, USA
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Department of Hematology/Oncology, Fox Chase Cancer Center, Temple Health, Philadelphia, USA
      name:Department of Hematology/Oncology, Fox Chase Cancer Center, Temple Health, Philadelphia, USA
      name:Department of Hematology/Oncology, Fox Chase Cancer Center, Temple Health, Philadelphia, USA
      name:Department of Hematology/Oncology, Fox Chase Cancer Center, Temple Health, Philadelphia, USA
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(158)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

3.81s.

LINK . SPRINGER . COM {}